Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Gain Therapeutics, Inc.

NASDAQ: GANX · Life Sciences · 5 alerts · CIK 1819411

Share price
$0.9402Close, Nov 16
Market cap
$41.9M
Shares outstanding
44.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Gain Therapeutics, Inc. filings on SEC EDGAR ↗

4:09 PM ET 10-Q
Financial Results

Gain Therapeutics Q3 2026 Results: Net Loss of $3.16M, Loss Narrows

Gain Therapeutics reported a net loss of $13.4 million for the nine months ended September 30, 2026, with cash and cash equivalents decreasing to $11.7 million from $20.8 million at year-end 2025. The company highlighted its ongoing reliance on additional financing to support its Magellan™ platform and clinical development programs.

Key figure
Net loss $3.16M
4:07 PM ET 8-K
Financial Results

Gain Therapeutics Financial Results

Gain Therapeutics reported financial results for the third quarter of 2026, highlighted by long-term Phase 1b data for rexaceract showing no motor symptom progression in Parkinson’s disease patients over 12 months. The company plans to initiate a Phase 2 clinical trial for rexaceract in Q1 2027 and select an initial therapeutic indication for its second candidate, GT-04686, by the end of 2026.

Term
Q3 2026

“The third quarter marked an important period of progress for Gain, highlighted by the presentation of long-term open-label data from the Phase 1b trial of rexaceract in Parkinson’s disease (PD). After 12 months of dosing with rexaceract, participants enrolled in the study showed no progression of Parkinson’s disease motor symptoms.”

Gene Mack, President and CEO of Gain Therapeutics

“As we approach the start of the Phase 2 clinical trial of rexaceract, which we expect to initiate during Q1 2027 after confirming updates to our trial design during Q4 2026, we plan to select an initial therapeutic indication to advance GT-04686 into the clinic.”

Gene Mack, President and CEO of Gain Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.